Home / Companies / News /  Wockhardt to manufacture and supply Sputnik V, Sputnik Light covid vaccine

Pharmaceutical company Wockhardt on Friday announced that the company has entered into an agreement with Enso Healthcare DMCC (Enso), a company incorporated in Dubai, UAE and Human Vaccine LLC (HV), a wholly owned subsidiary of the the sovereign wealth fund of the Russian Federation (RDIF), for the manufacture and supply of the Sputnik V/Sputnik Light vaccine against Covid-19. 

‘’Subject to requisite approvals and other conditions, upon successful technology transfer from HV to the company, the company will manufacture and supply to Enso upto 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine against Covid-19,'' Wockhardt said in a statement.

The agreement between the Company, HV, Enso was reached under the aegis of Enso, RDIF's coordination partner for sourcing Sputnik vaccine in India.

Shares of Wockhardt were trading over 5% higher to 514 per share on the BSE in Friday's early deals.

Indian pharma company Panacea Biotec Ltd has also agreed to produce up to 25 million doses of the Sputnik V COVID-19 vaccine using the drug substance made by Russia's Generium. Panacea will then supply the doses to drugmaker Dr Reddy's Laboratories for distribution in the country, the company informed last week.

Dr Reddy's, which has tied up with Russian Direct Investment Fund (RDIF) for Sputnik V in India, soft launched the vaccine in India in May 2021, after receiving Emergency Use Authorization (EUA) in April 2021. In September 2020, the company partnered with RDIF to conduct the clinical trials of Sputnik V and distribute the vaccine in India.

Sputnik V uses two different vectors for the two shots in a course of vaccination. Its efficacy was determined to be 91.6% as per an article published in the medical journal Lancet.

In July, Russian envoy Nikolay Kudashev as quoted by news agency ANI had said that the single-dose Sputnik Light Covid-19 vaccine is expected to launch soon in India.

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V coronavirus vaccine.

The Russian Direct Investment Fund (RDIF) had earlier said that it demonstrates 78.6% to 83.7% efficacy among the elderly, as per real-world data collected by the Ministry of Health of the Buenos Aires province (Argentina).

The vaccine has been developed by the Russian Ministry of Health, the Gamaleya National Research Centre of Epidemiology and Microbiology and the RDIF.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less

Recommended For You

Trending Stocks

Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout